Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin

Blood

Volumn 106, Issue 12, 2005, Pages 3791-3796

  Warkentin, Theodore E ^a   Cook, Richard J ^b   Marder, Victor J ^b   Sheppard, Jo Ann I ^b   Moore, Jane C ^b   Eriksson, Bengt I ^b   Greinacher, Andreas ^b   Kelton, John G ^b  

^a HAMILTON REGIONAL LABORATORY MEDICINE PROGRAM   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DANAPAROID; DESULFATOHIRUDIN; ENOXAPARIN; FONDAPARINUX; HEPARIN; HEPARIN PLATELET FACTOR 4 ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; POLYSACCHARIDE; THROMBOCYTE FACTOR 4;

ANTIBODY BLOOD LEVEL; ANTIBODY PRODUCTION; ANTIGEN BINDING; ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSS REACTION; DEEP VEIN THROMBOSIS; DOUBLE BLIND PROCEDURE; DRUG PROTEIN BINDING; DRUG SAFETY; FREQUENCY ANALYSIS; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; HUMAN CELL; IMMUNOGENICITY; KNEE ARTHROPLASTY; MAJOR CLINICAL STUDY; POSTOPERATIVE THROMBOSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; THROMBOSIS PREVENTION; TOTAL HIP PROSTHESIS;

EID: 28444494385     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2005-05-1938     Document Type: Article

References (45)

1. Lormeau JC, Herault JP. The effect of the synthetic pentasaccharide SR 90107/ORG 31540 on thrombin generation ex vivo is uniquely due to ATIII-mediated neutralization of factor Xa. Thromb Haemost. 1995;74:1474-1477.
2. Turpie AG, Bauer KA, Eriksson BI, Lassen MR. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch Intern Med. 2002;162:1833-1840.
3. Büller HR, Davidson BL, Decousus H, et al. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis. Ann Intern Med. 2004;140:867-873.
4. Matisse Investigators. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med. 2003;349:1695-1702.
5. Aster RH. Heparin-induced thrombocytopenia and thrombosis. N Engl J Med. 1995;332:1374-1376.
6. Chong BH. Heparin-induced thrombocytopenia. J Thromb Haemost. 2003;1:1471-1478.
7. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med. 1995;332:1330-1335.
8. Greinacher A, Eichler P, Lietz T, Warkentin TE. Replacement of unfractionated heparin by low-molecular-weight heparin for postorthopedic surgery antithrombotic prophylaxis lowers the overall risk of symptomatic thrombosis because of a lower frequency of heparin-induced thrombocytopenia [letter]. Blood. 2005;106:2921-2922.
9. Rauova L, Poncz M, McKenzie SE, et al. Ultralarge complexes of PF4 and heparin are central to the pathogenesis of heparin-induced thrombocytopenia. Blood. 2005;105:131-138.
10. Maccarana M, Lindahl U. Mode of interaction between platelet factor 4 and heparin. Glycobiology. 1993;3:271-277.
11. Greinacher A, Alban S, Dummel V, Franz G, Mueller-Eckhardt C. Characterization of the structural requirements for a carbohydrate based anticoagulant with a reduced risk of inducing the immunological type of heparin-associated thrombocytopenia. Thromb Haemost. 1995;74:886-892.
12. Visentin GP, Moghaddam M, Beery SE, McFarland JG, Aster RH. Heparin is not required for detection of antibodies associated with heparin-induced thrombocytopenia/thrombosis. J Lab Clin Med. 2001;138:22-31.
13. Alban S, Greinacher A. Role of sulfated polysaccharides in the pathogenesis of heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A, eds. Heparin-induced Thrombocytopenia. 3rd ed. New York, NY: Marcel Dekker; 2004:197-221.
14. Bauer KA, Eriksson BI, Lassen MR, Turpie AGG, for the Steering Committee of the Pentasaccharide in Major Knee Surgery Study. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N Engl J Med. 2001;345:1305-1310.
15. Turpie AGG, Bauer KA, Eriksson BI, Lassen MR, for the Pentathlon 2000 Study Steering Committee. Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial. Lancet. 2002;359:1721-1726.
16. Greinacher A, Eichler P, Albrecht D, Strobel U, Pötzsch B, Eriksson BI. Antihirudin antibodies following low-dose subcutaneous treatment with desirudin for thrombosis prophylaxis after hip-replacement surgery: incidence and clinical relevance. Blood. 2003;101:2617-2619.
17. Eriksson BI, Ekman S, Kaelebo P, Zachrisson B, Bach D, Close P. Prevention of deep-vein thrombosis after total hip replacement: direct thrombin inhibition with recombinant hirudin, CGP 39393. Lancet. 1996;347:635-639.
18. Horsewood P, Warkentin TE, Hayward CPM, Kelton JG. The epitope specificity of heparin-induced thrombocytopenia. Br J Haematol. 1996;95:161-167.
19. Warkentin TE, Hayward CPM, Smith CA, Kelly PM, Kelton JG. Determinants of platelet variability when testing for heparin-induced thrombocytopenia. J Lab Clin Med. 1992;120:371-379.
20. Newman PM, Swanson RL, Chong BH. Heparin-induced thrombocytopenia: IgG binding to PF4-heparin complexes in the fluid phase and cross-reactivity with low molecular weight heparin and heparinoid. Thromb Haemost. 1998;80:292-297.
21. Lindhoff-Last E, Gerdsen F, Ackermann H, Bauersachs R. Determination of heparin-platelet factor 4-IgG antibodies improves diagnosis of heparin-induced thrombocytopenia. Br J Haematol. 2001;113:886-890.
22. Donat F, Duret JP, Santoni A, et al. The pharmacokinetics of fondaparinux sodium in healthy volunteers. Clin Pharmacokinet. 2002;41(suppl 2):1-9.
23. Warkentin TE, Roberts RS, Hirsh J, Kelton JG. An improved definition of immune heparin-induced thrombocytopenia in postoperative orthopedic patients. Arch Intern Med. 2003;163:2518-2524.
24. Jewell N, van der Laan M. Generalizations of current status data with applications. Lifetime Data Anal. 1995;1:101-110.
25. Sun J. A nonparametric test for interval censored failure time data with applications to AIDS studies. Stat Med. 1995;15:1387-1395.
26. Agresti A. Categorical Data Analysis. New York, NY; Wiley; 1990.
27. Cox DR, Snell EJ. Analysis of Binary Data. New York, NY: Chapman & Hall; 1989.
28. Pouplard C, May MA, Iochmann S, et al. Antibodies to platelet factor 4-heparin after cardiopulmonary bypass in patients anticoagulated with unfractionated heparin or a low-molecular-weight heparin: clinical implications for heparin-induced thrombocytopenia. Circulation. 1999;99:2530-2536.
29. Ahmad S, Haas S, Hoppensteadt DA, et al. Differential effects of clivarin and heparin in patients undergoing hip and knee surgery for the generation of anti-heparin-platelet factor 4 antibodies. Thromb Res. 2002;108:49-55.
30. Lindhoff-Last E, Nakov R, Misselwitz F, Breddin HK, Bauersachs R. Incidence and clinical relevance of heparin-induced antibodies in patients with deep vein thrombosis treated with unfractionated heparin or low-molecular-weight heparin. Br J Haematol. 2002;118:1137-1142.
31. Greinacher A, Mueller-Eckhardt C. Heparin-associated thrombocytopenia: the antibody is not heparin specific. Thromb Haemost. 1992;67:545-549.
32. Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia: recognition, treatment, and prevention. The 7th ACCP Consensus Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(3 suppl):311S-337S.
33. Hirsh J, Raschke R. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(3 suppl):188S-203S.
34. Elalamy I, Lecrubier C, Potevin C, et al. Absence of in vitro cross-reaction of pentasaccharide with the plasma heparin-dependent factor of twenty-five patients with heparin-associated thrombocytopenia. Thromb Haemost. 1995;74:1384-1385.
35. Savi P, Chong BH, Greinacher A, et al. Effect of fondaparinux on platelet activation in the presence of heparin-dependent antibodies: a blinded comparative multicenter study with unfractionated heparin. Blood. 2005;105:139-144.
36. Suh JS, Aster RH, Visentin GP. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis recognize different epitopes on heparin:platelet factor 4. Blood. 1998;91:916-922.
37. Li ZQ, Liu W, Park KS, et al. Defining a second epitope for heparin-induced thrombocytopenia/thrombosis antibodies using KKO, a murine HIT-like monoclonal antibody. Blood. 2002;99:1230-1236.
38. Greinacher A, Michels I, Schafer M, Kiefel V, Mueller-Eckhardt C. Heparin-associated thrombocytopenia in a patient treated with polysulphated chondroitin sulphate: evidence for immunological crossreactivity between heparin and polysulphated glycosaminoglycan. Br J Haematol. 1992;81:252-254.
39. Goad KE, Horne MK III, Gralnick HR. Pentosan-induced thrombocytopenia: support for an immune complex mechanism. Br J Haematol. 1994;88:803-808.
40. Rosenthal MA, Rischin D, McArthur G, et al. Treatment with the novel anti-angiogenic agent PI-88 is associated with immune-mediated thrombocytopenia. Ann Oncol. 2002;13:770-776.
41. Greinacher A, Gopinadhan M, Guenther J, et al. Fondaparinux interacts with platelet factor 4-challenge of a dogma in hemostasis [abstract]. Hämostasiologie. 2005;25:A55.
42. Kovacs MJ. Successful treatment of heparin induced thrombocytopenia (HIT) with fondaparinux. Thromb Haemost. 2005;93:999-1000.
43. Rubin N, Rubin J. Treatment of heparin induced thrombocytopenia with thrombosis (HITT) in pregnancy with fondaparinux [abstract]. Blood. 2003;102:120b.
44. Parody R, Oliver A, Souto JC, Fontcuberta J. Fondaparinux (Arixtra) as an alternative antithrombotic prophylaxis when there is hypersensitivity to low molecular weight and unfractionated heparins. Haematologica. 2003;88:ECR32.
45. Ranze O, Eichner A, Lubenow N, Kempf R, Greinacher A. The use of low-molecular-weight heparins in heparin-induced thrombocytopenia (HIT): a cohort study [abstract]. Ann Hematol. 2000;79(suppl 1):P198.